Article 1 to 1 out of 1 concerning Vanderbilt-Ingram Cancer Center
Affymetrix Signs Three-Year Translational Medicine Agreement With Vanderbilt-Ingram Cancer Center(01/26/2007) Research Team to Use Affymetrix GeneChip(R) Technology to Develop Applications for Cancer and HIV/AIDS Affymetrix Inc. and Vanderbilt-Ingram Cancer Center announced that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, ...
Top